ImmunoVaccine Inc. (TSE:IMV) insider Pierre Labbé purchased 25,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was bought at an average cost of C$1.22 per share, for a total transaction of C$30,500.00.
Pierre Labbé also recently made the following trade(s):
- On Friday, July 28th, Pierre Labbé purchased 26,825 shares of ImmunoVaccine stock. The stock was bought at an average cost of C$1.22 per share, for a total transaction of C$32,726.50.
Shares of ImmunoVaccine Inc. (IMV) traded up 3.45% during midday trading on Tuesday, reaching $1.20. The company had a trading volume of 10,805 shares. The company has a 50 day moving average of $1.20 and a 200 day moving average of $1.19. The firm’s market capitalization is $143.84 million. ImmunoVaccine Inc. has a 12-month low of $0.51 and a 12-month high of $1.70.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/08/immunovaccine-inc-tseimv-insider-purchases-c30500-00-in-stock-updated-updated.html.
ImmunoVaccine Company Profile
Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company’s DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
Receive News & Ratings for ImmunoVaccine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
